HMR Anzemet Study Validates Switch From Kytril At USC Cancer Center
Executive Summary
A patient survey study of efficacy outcomes for Hoechst Marion Roussel's antiemetic Anzemet helped justify a switch by the University of Southern California Norris Cancer Center from SmithKline Beecham's more expensive Kytril.